{
    "clinical_study": {
        "@rank": "51917", 
        "acronym": "SUCCESS", 
        "arm_group": {
            "arm_group_label": "Group 1"
        }, 
        "brief_summary": {
            "textblock": "This study is to obtain the characteristics and treatment parttern of the unresectable HCC\n      patients who are candidates for systemic therapy and in whom a decision to treat with\n      sorafenib from early stage of TACE treatment course (concomitantly use no later than the 3rd\n      TACE procedure) has been made under real-life practice conditions.this study will also\n      conclude the safety and effectiveness of combination in uHCC patients."
        }, 
        "brief_title": "Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma, Hepatocellular", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with histologically/ cytologically documented or radiographically diagnosed\n             unresectable HCC who are candidates for systemic therapy and for whom a decision to\n             treat with sorafenib has been made. Radiographic diagnosis needs typical findings of\n             HCC by radiographic method i.e. on multi-dimensional dynamic CT, CT hepatic\n             arteriography (CTHA)/CT arterial portography (CTAP) or MRI;\n\n          -  Patients receive the first dose of sorafenib no later than 1 week (<=7days) after the\n             3rd TACE procedure\n\n          -  Patients did not receive other prior systemic treatment by using target therapy\n\n          -  Patients must sign the informed consent form;\n\n          -  Patients must have a life expectancy of at least 3 months;\n\n          -  The physician must be willing to complete and submit all CRFs;\n\n          -  The physician must be willing to submit to a site audit with verification of source\n             documents and validation of data reported;\n\n        Exclusion Criteria:\n\n          -  The first dose of sorafenib 7 days after the 3nd TACE procedure\n\n          -  Exclusion criteria must follow the approved local product information"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Unresectable HCC patients and be candidates for concomitantly systemic therapy with\n        sorafenib + TACE. Considering the local practice and possible clinical benefits, sorafenib\n         should not be initiated later than 7 days after the 3rd TACE course. No prior tartgeted\n        therapy."
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01839630", 
            "org_study_id": "16608", 
            "secondary_id": "NX1216CN"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "sorafenib treatment (including dose, duration, modification) and TACE procedure are desided by the investigator", 
            "intervention_name": "Sorafenib (Nexavar, BAY43-9006)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Sorafenib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Sorafenib", 
            "Hepatocellular cancer", 
            "TACE combination", 
            "Treatment pattern", 
            "Safety", 
            "Effectiveness"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "China"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "Study of Unresectable HCC Treated Concomitantly With TACE and Sorafenib in Chinese Patients", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patient characteristics are hepatic virus infection status, surgery history, tumor size, number of tumor, macroscopic vascular invasion (MVI), extra-hepatic spread (EHS), cirrhosis, ECOG score, Child-Pugh score, BCLC stage, etc.", 
            "measure": "Summarized patient characteristics", 
            "safety_issue": "No", 
            "time_frame": "up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01839630"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of participants with adverse events( AE) and Serious adverse events(SAE) as a measure of safety and tolorability", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "overall survival (OS) by the mRECIST (Modified Response Evaluation Criteria in Solid Tumor) Criteria for treatment of uHCC patients", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "progression-free survival (PFS) by the mRECIST for treatment of uHCC patients", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "time to progression (TTP) by the mRECIST for treatment of uHCC patients", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "response rate (RR) by the mRECIST for treatment of uHCC patients", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "Clinical control Rate(DCR) by the mRECIST for treatment of uHCC patients", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "Clinical benefit rate (CBR) by the mRECIST for treatment of uHCC patients", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "description": "Treatment pattern included: Duration and dosage of Sorafenib treatment; reason for Sorafenib dosage modification/discontinuation; anticancer combination therapy; treatment after radiographic relapse; comorbidities and their impact on disease outcome.", 
                "measure": "Treatment pattern of Sorafenib", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2014"
    }
}